The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Preclinical Evaluation of Genexol-PM, a Nanoparticle Formulation of Paclitaxel, as a Novel Radiosensitizer for the Treatment of Non-Small Cell Lung Cancer
Open accessAbstract
Purpose A key research objective in radiation oncology is to identify agents that can improve chemoradiation therapy. Nanoparticle (NP) chemotherapeutics possess several properties, such as preferential accumulation in tumors, that are uniquely suited for chemoradiation therapy. To facilitate the clinical translation of NP chemotherapeutics in chemoradiation therapy, we conducted preclinical evaluation of Genexol-PM, the only clinically approved NP chemotherapeutic with a controlled drug release profile, as a radiosensitizer using non-small cell lung cancer (NSCLC) as a model disease.Methods and materials The physical characteristics and drug release profile of Genexol-PM were characterized. Genexol-PM's efficacy as a radiosensitizer was evaluated in vitro using NSCLC cell lines and in vivo using mouse xenograft models of NSCLC. Paclitaxel dose to normal lung and liver after Genexol-PM administration were quantified and compared with that after Taxol administration.Results Genexol-PM has a size of 23.91 ± 0.41 nm and surface charge of -8.1 ± 3.1 mV. It releases paclitaxel in a controlled release profile. In vitro evaluation of Genexol-PM as a radiosensitizer showed it is an effective radiosensitizer and is more effective than Taxol, its small molecule counterpart, at the half maximal inhibitory concentration. In vivo study of Genexol-PM as a radiosensitizer demonstrated that it is more effective as a radiosensitizer than Taxol. We also found that Genexol-PM leads to lower paclitaxel exposure to normal lung tissue than Taxol at 6 hours postadministration.Conclusions We have demonstrated that Genexol-PM is more effective than Taxol as a radiosensitizer in the preclinical setting and holds high potential for clinical translation. Our data support the clinical evaluation of Genexol-PM in chemoradiation therapy for NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Under sink conditions, paclitaxel was slowly released from the micelle with 65% released at 24 hours and 95% released at 48 hours [110].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [110]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The clinically approved polymeric micelle formulation of paclitaxel Genexol® PM formulation exploits mPEG-b-PDLLA to solubilize paclitaxel and is discussed in greater detail in Section 5.3 [110].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [110]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“For instance, micelle systems prepared using PCL-b-PEG-b-PCL displayed high loading up to 28% of paclitaxel [83].”
From Recent Advances in Nanomicelles Delivery Systems. (2020) · cites this paper as [83]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
Forastiere, A. A., Goepfert, H., Maor, M. H., Pajak, T. F., Weber, R. S., Morrison, W. H., Glisson, B. S., Trotti, A., Ridge, J. A., Chao, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031317 · Cited by 3,161
Analysis of serial measurements in medical research.
Matthews, J. N. S., Altman, D. G., Campbell, M. J., & Royston, P. J. (1990) · BMJ · doi:10.1136/bmj.300.6719.230 · Cited by 3,137
Nanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J. M., Wang, A. Z., Langer, R., & Farokhzad, O. C. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,685
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic‐Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,774
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,739
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,575
O’Connell, M. J., Martenson, J. A., Wieand, H. S., Krook, J. E., Macdonald, J. S., Haller, D. G., Mayer, R. J., Gunderson, L. L., & Rich, T. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408253310803 · Cited by 1,131
Fournel, P., Robinet, G., Thomas, P. A., Souquet, P.-J., Léna, H., Vergnenégre, A., Delhoume, J. Y., Treut, J. H. L., Silvani, J.-A., Dansin, É., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.070 · Cited by 543
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541
The concurrent chemoradiation paradigm—general principles
Seiwert, T. Y., Salama, J. K., & Vokes, E. E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0714 · Cited by 452
Flagged first, then by citations
1 of the 22 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–267 of 267
HPM OF ESTROGEN MODEL ON THE DYNAMICS OF BREAST CANCER
Govindarajan, A., Balamuralitharan, S., & Sundaresan, T. (2018) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1000/1/012095 · Cited by 4
Bayoumi, N. A., & El‐Kolaly, M. T. (2021) · Radiochimica Acta · doi:10.1515/ract-2020-0098 · Cited by 4
Liu, H., Nadar, R. A., Fauzia, R. P., Laan, A. C., Doeswijk, B., Wang, R., van der Meer, A. J. G. M., van Cooten, Q., Carroll, E. C., Eelkema, R., et al. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202200224 · Cited by 4
Nanotechnology-based healthcare engineering products and recent patents—an update
Bhattacharyya, S., Sandhu, K., & Chockalingam, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91182-5.00004-8 · Cited by 4
Emerging Trends in Nanotechnology for Diagnosis and Therapy of Lung Cancer
Rohra, N., Gore, M., Dyawanapelly, S., Tambe, M., Gautam, A., Suvarna, M., Jain, R. D., & Dandekar, P. P. (2018) · CRC Press eBooks · doi:10.1201/9781351031585-4 · Cited by 4
Evolution of Controlled Drug Delivery Systems
Janapareddi, K., Jasti, B., & Li, X. (2016) · Drug Delivery · doi:10.1002/9781118833322.ch15 · Cited by 4
PEGylated Nanocarriers for Gene Therapy
Mishra, L., Kumari, L., Sharma, Y., Chahar, K., Khare, S., Patel, P., Singh, D., & Kurmi, B. D. (2025) · Springer eBooks · doi:10.1007/978-981-97-7316-9_8 · Cited by 3
Bao, X., Zheng, Z., Li, M., Wang, X., Zhao, Q., Wang, H., Xin, Y., & Jiang, X. M. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.217234 · Cited by 4
Rapid in vivo release of paclitaxel from polymeric micelles
He, H., Qi, J., Lü, Y., & Wu, W. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.11.034 · Cited by 4
Shaping Function: Polymeric 3D Systems With Unconventional Geometries for Biomedical Applications
Perfeito, F. G., Oliveira, M., & Mano, J. F. (2026) · Small · doi:10.1002/smll.202514666 · Cited by 3
Tiwari, S., Kaur, H., Anees, M., Gupta, P., Dalela, M., Kharbanda, S. M., & Singh, H. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122343 · Cited by 3
Knowledge-Based Design of Multifunctional Polymeric Nanoparticles
Behnke, M., Holick, C. T., Vollrath, A., Schubert, S., & Schubert, U. S. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_649 · Cited by 3
Nanotheranostic Approach for the Management of Colorectal Cancer
Sharma, S., Kuppusamy, G., Chowdhury, P. R., & Pamu, D. (2023) · Nanoscience & Nanotechnology-Asia · doi:10.2174/2210681213666230823160616 · Cited by 3
Development in efficacy assessment in relevant oncology models for breast cancer nanomedicine
Kumar, G., Rao, V., & Kumar, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820016-2.00013-6 · Cited by 3
Nath, R., Roy, R., Mondal, B., Bhattacharya, B., & Ravi, L. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i38b32093 · Cited by 3
An Overview of Nanoparticle Biocompatibility for Their Use in Nanomedicine
Boyles, M. S. P., Powell, L. G., Kermanizadeh, A., Johnston, H. J., Rothen‐Rutishauser, B., Stone, V., & Clift, M. J. D. (2016) · doi:10.1002/9783527800681.ch18 · Cited by 3
Macro-, micro- and nanoscale drug delivery systems in oncotherapy: current clinical status
Tărăbuță, P. A. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214365 · Cited by 2
Brunzell, E., Högström, Y. K., Hernández, M. L., Pedersen, J. S., & Bergström, M. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.139373 · Cited by 2
Dong, Y., Zheng, Y., Zhang, J., Lv, X., Hong, H., Zheng, Y., Wang, R., & Gong, J. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105101 · Cited by 2
Rotavirus-Inspired Nanointerface Engineered Biosensors for All-in-One Cancer Diagnosis
Zhu, Y., Ren, Q., Liu, D., Jiang, L., Yang, Y., Qiu, R., Li, Z., & Zhang, M. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c05210 · Cited by 2
Concluding remarks and future perspective of combination drug delivery systems
Nasser, T. A., AbdElhamid, A. S., Teleb, M., Khattab, S. N., Bekhit, A. A., Elkhodairy, K. A., & Elzoghby, A. O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85873-1.00004-6 · Cited by 2
Polymeric micelles in dermal and transdermal drug delivery
Ali, M. A., & Gould, M. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89868-3.00009-4 · Cited by 3
Latest advances in triple-negative breast cancer nanotheranostics
Rezigue, M. M., Obeid, M. A., Amawi, H. A., & Aljabali, A. A. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821013-0.00016-7 · Cited by 2
Cutrona, M. B. (2025) · Methods in cell biology · doi:10.1016/bs.mcb.2025.10.002 · Cited by 1
Gahtani, R. M., Barkat, H. A., Hasan, N., Alanezi, A. A., Ansari, M. A., Hani, U., Fatima, F., & Barkat, M. A. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108231 · Cited by 1
Polymer Drug Conjugate: A Revolution in Drug Delivery
Singh, C. K., & Deb, P. K. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03411-9 · Cited by 1
Emara, H. M., Mohammad, A. M., & Allam, N. K. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108978
Multifunctional Nanoparticles in Radiation Oncology: An Emerging Paradigm
Belz, J., Ngwa, W. F., Korideck, H., Cormack, R. A., Berbeco, R. I., Makrigiorgos, M. G., Sridhar, S., & Kumar, R. (2014) · ACS symposium series · doi:10.1021/bk-2014-1183.ch005 · Cited by 1
Ao, L. (2016) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2017.004 · Cited by 1
Performance Analysis of Nanoparticles in Healthcare and Biomedical Applications
Ruba, T., Tamilselvi, R., Beham, M. P., & Muthukumaran, K. (2019) · Lecture notes in networks and systems · doi:10.1007/978-981-13-3765-9_2 · Cited by 1
Youngren-Ortiz, S. R., & Chougule, M. B. (2017) · Europe PMC (PubMed Central) · Cited by 1
Nanomedicine Applications in Cancer Treatment
Fraguas‐Sánchez, A. I., Martín‐Sabroso, C., Lozza, I., & Torres‐Suárez, A. I. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_294-1 · Cited by 1
Udin, S. M., Maarof, H., & Rahman, N. A. (2023) · ChemistrySelect · doi:10.1002/slct.202301022 · Cited by 1
Organic Nanomaterials Loaded with Cytotoxic Agents: A Therapeutic Alternative Against Cancer
Mejía-Méndez, J. L., López-Mena, E. R., Navarro-López, D. E., Sánchez-Arreola, E., & Cerro‐López, M. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_267 · Cited by 1
Nanomedicine’s Transformative Role in Advancing Cancer Treatment
Vengurlekar, J. R., Bhaware, B. B., Prasad, T., & Sarkar, J. (2024) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-72467-1_4 · Cited by 1
The Use of Immunomicelles to Treat Ovarian Cancer
Khan, D. R. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.16.002863 · Cited by 1
Recent Trends for Nanomedicine Safety
Mukherjee, B., Dutta, D., Ghosh, P., Paul, B., Sen, R., & Chakraborty, S. (2020) · Springer eBooks · doi:10.1007/978-981-15-6255-6_18 · Cited by 1
The Role of Nanotechnology for Diagnostic and Therapy Strategies in Lung Cancer
Holder, J. E., Al-Yozbaki, M., & Wilson, C. M. (2022) · Medical radiology · doi:10.1007/174_2022_342 · Cited by 1
Microfluidics Applications in Cancer Drug Delivery
Zhang, H., & Shen, Y. (2016) · Wiley eBooks · doi:10.1002/9783527694396.ch5 · Cited by 1
Review of Commercially Available Nano-Drugs and Nano-Delivery Systems: Challenges and PerspectivesPreprint
Boudovitch, D., Sakaya, A., Uzundurukan, A., Leroux, J.-Y., & Fuoco, D. (2023) · Preprints.org · doi:10.20944/preprints202312.1480.v1 · Cited by 1
Cheng, H., Hsieh, S., Chen, T., Hung, P.-F., & Pan, S. (2016) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2016.06.050
Nanopharmaceuticals: Characteristics of importance for pharmaceutical practice
Bubić-Pajić, N., Gatarić, B., Čivčija, J., & Vuleta, G. (2017) · Arhiv za farmaciju · doi:10.5937/arhfarm1704265b
Chapter 9 Nanomaterials and Nanotechnologies for Photon Radiation Enhanced Cancer Treatment
Adlienė, D. (2018) · NATO science for peace and security series. B, Physics and biophysics · doi:10.1007/978-94-024-1544-5_9
Sonic structures and their visual forms
Lock, D. (2012) · Research Online (University of Wollongong)
Newly Emerged 2D Mesoporous Silica Nanoparticles: Role in Target-Setting Biomedicines
Srivastava, P., Hira, S. K., & Manna, P. P. (2022) · Materials horizons · doi:10.1007/978-981-16-8538-5_9
Mendes (2018) · Digital Repository Service (Northeastern University) · doi:10.17760/d20292338
Nanomedicines in Treatment of Cancer
Akhtar, B., Tanveer, A., Sharif, A., Anjum, F., Shahid, M., & Zia, S. (2023) · Learning materials in biosciences · doi:10.1007/978-981-99-7626-3_6
Nanostructured Drug Delivery Systems for Targeted Therapy of Cancer
Barghi, L. (2023) · Scientific Journal of Kurdistan University of Medical Sciences · doi:10.61186/sjku.28.5.122
Nanomedicine for cancer diagnosis and therapy
Kaleem, M., Anjum, V., Thool, M., Hasan, A., Ahmad, S., & Tabrez, S. S. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33984-4.00008-0
Clinical Validations of Localized Cancer Nanomedicine
Chandpa, H. H., Naskar, S., Kumbhar, P. A., Singh, A., & Meena, J. (2025) · Springer eBooks · doi:10.1007/978-981-95-0938-6_7
Nanomedicine Applications in Cancer Treatment
Fraguas‐Sánchez, A. I., Martín‐Sabroso, C., Lozza, I., & Torres‐Suárez, A. I. (2025) · Springer eBooks · doi:10.1007/978-3-032-00773-5_294
Pi, F., Deng, X., Xue, Q., Zheng, L., Liu, H., Yang, F., & Chen, T. (2023) · Figshare · doi:10.6084/m9.figshare.22625528
Surface engineered hybrid nanocarriers for cancer treatment
Mielcarek, A. (2020) · theses.fr (ABES) · doi:10.70675/8de5d165z1c5ez4039z9dffze2f9504e0e67
Almehmady, A. M., Alahmadi, A. A., Hakami, A., Ali, E. M. M., Kalantan, A. A., Aljagthmi, A., & Ahmed, T. A. (2026) · IET Nanobiotechnology · doi:10.1049/nbt2/4890307
Ultrasound-responsive drug nanocarriers in oncology: key determinants of therapeutic performance
Reete, F., Wu, Z., & Thakur, S. S. (2026) · Journal of Liposome Research · doi:10.1080/08982104.2026.2681623
Artificial intelligence in cancer medicine: Nanotherapeutics and integrative approaches
Hassan, N., Ali, U., & Ali, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44021-2.00012-9
Prajapati, S., Kumar, A., & Singh, R. (2026) · Biomedical Materials · doi:10.1088/1748-605x/ae83f7
Advances in nanocarrier-enabled theranostic strategies for lung cancer diagnosis and management.
Mehta, H., Yadav, B., Acharya, S., & Shah, B. M. (2026) · Journal of Biomaterials Science. Polymer Edition · doi:10.1080/09205063.2026.2696918
Kumar, R. R., & Enoch, I. V. M. V. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109518
Recent updates on clinical trials associated with stimuli-responsive nanocarriers
Peyman, M., Parandavar, E., & Mohammadpour, Z. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33641-6.00027-0
Mansour, S. T., & Mamdouh, W. (2026) · Cancer Nanotechnology · doi:10.1186/s12645-026-00412-y
Aggarwal, R., Gupta, S., Abourehab, M. A. S., Leharwani, M., Gupta, G., Goh, K. W., & Kesharwani, P. (2026) · European Polymer Journal · doi:10.1016/j.eurpolymj.2026.115057
David, S. R., Kifli, A. A. A., & Rajabalaya, R. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108966
Engineering Next-Generation Taxane Nanomedicines for Clinical Translation
Nagpal, D., Nagpal, S., Kathuria, H., Pandey, M. M., Mittal, V., & Kaushik, D. (2026) · Macromol—A Journal of Macromolecular Research · doi:10.3390/macromol6040087
Metadata
- Authors
- Werner, M. E., Cummings, N. D., Sethi, M., Wang, E. C., Sukumar, R., Moore, D. T., & Wang, A. Z.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Wang, Andrew Z.
- Venue
- International Journal of Radiation Oncology*Biology*Physics
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 86
- Issue
- 3
- Pages
- 463-468
- ISSN
- 0360-3016 (ISSN-L)
- PMC
- PMC3750707
- OpenAlex
- W2169498622
- Cited by
- 267
- References
- 22
- Citations by year
- 2026: 20 · 2025: 23 · 2024: 21 · 2023: 31 · 2022: 24 · 2021: 18 · 2020: 23 · 2019: 18 · 2018: 23 · 2017: 19 · 2016: 22 · 2015: 12 · 2014: 8 · 2013: 4
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- International Journal of Radiation Oncology*Biology*Physics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5u54ca151652-05, 2k12ca120780-16)
- National Cancer Institute (5-K12-CA120780-01-05, U54‐CA151652, 1-U54-CA151652-01, K12-CA120780, R01CA178748)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- paclitaxel, nanoparticle drug delivery, radiosensitizers, non-small cell lung cancer, chemoradiotherapy, controlled drug release, nanoparticle size and surface charge, taxol comparison
- MeSH terms
- Animals, Antineoplastic Agents, Phytogenic, Carcinoma, Non-Small-Cell Lung, Lung, Lung Neoplasms, Mice, Nude, Polymers, Radiation-Sensitizing Agents, Paclitaxel, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tumor Burden, Mice, Nanoparticles, Chemoradiotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
